|
(Amherst, NH) –
A new generation of
diagnostic imaging agents that can target specific organs and even specific molecules
is poised to play the role of midwife to the birth of a new level of
disease detection and metabolic eavesdropping. The ability of this new
generation of diagnostic imaging agents to detect metabolic changes at the molecular
level has significant potential for improving visualization and quality of
care.
Targetable and activatable diagnostic imaging agents are gaining interest for a wide
range of diagnostic imaging applications that include cardiology, neurology and
soft tissue tumor detection. From amyloid plaques and soft tissue tumors
to myocardial perfusion and therapeutic nuclear medicine, the ability of
noninvasive diagnostics to detect pathologies, monitor therapeutic
outcomes, guide interventional procedures and play an active role in
disease therapies is positioned to increase dramatically.
Targeted and activatable diagnostic imaging agents offer a unique capability to
generate unambiguous images by exploiting specific molecular targets,
pathways or cellular processes. This new wave of diagnostic imaging agents signals a
paradigm shift in which the reagents take on new importance in corporate
business models alongside system hardware in revenue projections and
product line ROI.
These findings are
contained in a new and comprehensive report. Diagnostic Imaging Agents:
The Next Generation. The report contains in-depth analysis of the science,
technology, and market participants that are shaping the future of
diagnostic imaging.
|
